Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Quest for the Best Dual Orexin Receptor Antagonist (Daridorexant) for the Treatment of Insomnia Disorders
Christoph Boss, John Gatfield, Christine Brotschi, et al.
ChemMedChem (2020) Vol. 15, Iss. 23, pp. 2286-2305
Closed Access | Times Cited: 37

Showing 1-25 of 37 citing articles:

Hypocretins (orexins): The ultimate translational neuropeptides
Laura H. Jacobson, Daniël Hoyer, Luı́s de Lecea
Journal of Internal Medicine (2022) Vol. 291, Iss. 5, pp. 533-556
Closed Access | Times Cited: 71
Long-Term Safety and Tolerability of Daridorexant in Patients with Insomnia Disorder
Dieter Kunz, Yves Dauvilliers, Heike Beneš, et al.
CNS Drugs (2022) Vol. 37, Iss. 1, pp. 93-106
Open Access | Times Cited: 52
New Approved Drugs Appearing in the Pharmaceutical Market in 2022 Featuring Fragments of Tailor-Made Amino Acids and Fluorine
Nana Wang, Haibo Mei, Gagan Dhawan, et al.
Molecules (2023) Vol. 28, Iss. 9, pp. 3651-3651
Open Access | Times Cited: 28
Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia
Catherine Roch, Giorgio Bergamini, Michel A. Steiner, et al.
Psychopharmacology (2021) Vol. 238, Iss. 10, pp. 2693-2708
Open Access | Times Cited: 50
Discovery of Nivasorexant (ACT-539313): The First Selective Orexin-1 Receptor Antagonist (SO1RA) Investigated in Clinical Trials
Jodi T. Williams, Martin H. Bolli, Christine Brotschi, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 4, pp. 2337-2348
Closed Access | Times Cited: 6
Orexin Signaling: A Complex, Multifaceted Process
Natasha C. Dale, Daniël Hoyer, Laura H. Jacobson, et al.
Frontiers in Cellular Neuroscience (2022) Vol. 16
Open Access | Times Cited: 26
Targeting orexin receptors: Recent advances in the development of subtype selective or dual ligands for the treatment of neuropsychiatric disorders
Alessandro Bonifazi, Fabio Del Bello, Gianfabio Giorgioni, et al.
Medicinal Research Reviews (2023) Vol. 43, Iss. 5, pp. 1607-1667
Closed Access | Times Cited: 13
The present and future of synthetic orexin receptor agonists
Tsuyoshi Saitoh, Takeshi Sakurai
Peptides (2023) Vol. 167, pp. 171051-171051
Open Access | Times Cited: 13
Effects of daridorexant on rest/wake activity patterns and drinking in adult rats exposed to chronic ethanol vapor in adolescence
Leslie R. Amodeo, Derek N. Wills, Jason Benedict, et al.
Alcohol (2025)
Open Access
Development and pharmacological characterization of novel multi‐ calcitonin gene‐related peptide and pituitary adenylate cyclase‐activating peptide receptor antagonists
Zoe Tasma, Andrew Siow, Paul W. R. Harris, et al.
Headache The Journal of Head and Face Pain (2025)
Open Access
Discovery of IDOR-1117-1680, a dual orexin receptor antagonist with fast onset and short duration of action for the treatment of insomnia
Jean‐Philippe Surivet, Elise M. Jacob, Melanie Keßler, et al.
Bioorganic & Medicinal Chemistry (2025) Vol. 122, pp. 118132-118132
Closed Access
Dual orexin receptor antagonists as promising therapeutics for Alzheimer’s disease
Sydney M. Ragsdale, John M. Radovich, Isabel I. Coiduras, et al.
Deleted Journal (2025) Vol. 2, Iss. 1
Open Access
Orexin Receptor Antagonists and Insomnia
Xin Wu, Tao Xue, Zhouqing Chen, et al.
Current Psychiatry Reports (2022) Vol. 24, Iss. 10, pp. 509-521
Closed Access | Times Cited: 20
Number, Duration, and Distribution of Wake Bouts in Patients with Insomnia Disorder: Effect of Daridorexant and Zolpidem
Tobias Di Marco, Thomas E. Scammell, Michael Meinel, et al.
CNS Drugs (2023) Vol. 37, Iss. 7, pp. 639-653
Open Access | Times Cited: 10
The potential use of daridorexant in eating disorders: beyond the treatment of insomnia?
Alice Caldiroli, Letizia Maria Affaticati, Enrico Capuzzi, et al.
International Clinical Psychopharmacology (2024)
Closed Access | Times Cited: 3
Daridorexant for the Treatment of Insomnia
Christopher L. Robinson, Rajesh Supra, Evan Downs, et al.
Health psychology research (2022) Vol. 10, Iss. 3
Open Access | Times Cited: 15
Clinical safety of daridorexant in insomnia treatment: Analysis of FDA adverse event reports
Qi Wang, Qin Zhou, Zhiqiang Du, et al.
Journal of Affective Disorders (2024) Vol. 362, pp. 552-559
Closed Access | Times Cited: 2
Effect of Liver Cirrhosis on the Pharmacokinetics, Metabolism, and Tolerability of Daridorexant, A Novel Dual Orexin Receptor Antagonist
Benjamin Berger, Jasper Dingemanse, Giancarlo Sabattini, et al.
Clinical Pharmacokinetics (2021) Vol. 60, Iss. 10, pp. 1349-1360
Closed Access | Times Cited: 17
Peptidomic Approaches and Observations in Neurodegenerative Diseases
Besnik Muqaku, Patrick Oeckl
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 13, pp. 7332-7332
Open Access | Times Cited: 9
A Comprehensive Review of Daridorexant, a Dual-Orexin Receptor Antagonist as New Approach for the Treatment of Insomnia
Wojciech Ziemichód, Karolina Grabowska, Antonina Kurowska, et al.
Molecules (2022) Vol. 27, Iss. 18, pp. 6041-6041
Open Access | Times Cited: 9
Daridorexant, a Recently Approved Dual Orexin Receptor Antagonists (DORA) in Treatment of Insomnia
Dwaipayan Sarathi Chakraborty, Shouvik Choudhury, Sandeep Lahiry
Sleep Science (2023) Vol. 16, Iss. 02, pp. 256-264
Open Access | Times Cited: 5
Pharmacokinetic and pharmacodynamic interactions between daridorexant, a dual orexin receptor antagonist, and citalopram in healthy subjects
Benjamin Berger, Rüdiger Kornberger, Jasper Dingemanse
European Neuropsychopharmacology (2021) Vol. 51, pp. 90-104
Closed Access | Times Cited: 12
Daridorexant, a Recently Approved Dual Orexin Receptor Antagonists (DORA) in the Treatment of Insomnia
Dwaipayan Sarathi Chakraborty, Shouvik Choudhury, Sandeep Lahiry
Current Drug Research Reviews (2022) Vol. 15, Iss. 2, pp. 149-158
Closed Access | Times Cited: 8
Discovery, synthesis and SAR of 2-acyl-1-biarylmethyl pyrazolidines, dual orexin receptor antagonists designed as fast and short-acting sleeping drugs
Jean‐Philippe Surivet, Melanie Keßler, Catherine Vaillant, et al.
Bioorganic & Medicinal Chemistry (2024) Vol. 112, pp. 117892-117892
Closed Access | Times Cited: 1
Dual Orexin Receptor Antagonists as Promising Therapeutics for Alzheimer’s Disease
Sydney M. Ragsdale, Jenna Radovich, Isabel I. Coiduras, et al.
(2024)
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top